GlassScriptPhysician profile
Odai Abdalla
NPI 1689162786
$4,504.68
in general payments reported to CMS, 2019-2025
11 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,418 · 2024: $1,524 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Travel and Lodging: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.22 |
| Travel and Lodging | $2,011.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,988.68 | 2023-2025 | Wavewriter Alpha Prime 16, Vercise |
| Medtronic, INC. | $651.49 | 2023-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Synchromedii |
| Abbott Laboratories | $312.28 | 2023-2025 | Proclaim |
| Spr Therapeutics, INC | $198.82 | 2023-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.37 | 2023 | Relistor |
| Convatec INC. | $63.07 | 2025 | |
| Abbvie INC. | $51.38 | 2023-2025 | Botox |
| Sk Life Science, INC. | $29.87 | 2025 | |
| Averitas Pharma INC. | $29.06 | 2023-2024 | Qutenza |
| Avanos Medical | $26.35 | 2024 | Coolief* Cooled Radiofrequency |
| Pfizer INC. | $17.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odai Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.